(MedPage Today) — AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, successfully lowered blood pressure (BP) in people with uncontrolled or treatment-resistant hypertension in the BaxHTN trial.
Bedtime antihypertensives…